Stratos Wealth Partners, Ltd. Iovance Biotherapeutics, Inc. Transaction History

Stratos Wealth Partners, Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 26, 2022	SELL	$12.38 - $19.1 $172,998 - $266,903	-13,974 Closed	0 $0
Q4 2021 Jan 14, 2022	SELL	$16.55 - $27.63 $23,997 - $40,063	-1,450 Reduced 9.4%	13,974 $267,000
Q3 2021 Oct 19, 2021	SELL	$20.35 - $26.63 $127,228 - $166,490	-6,252 Reduced 28.84%	15,424 $380,000
Q2 2021 Jul 19, 2021	SELL	$16.33 - $33.07 $443,604 - $898,346	-27,165 Reduced 55.62%	21,676 $564,000
Q1 2021 Apr 27, 2021	SELL	$28.67 - $52.59 $22,047 - $40,441	-769 Reduced 1.55%	48,841 $1.55 Million
Q4 2020 Jan 29, 2021	BUY	$28.04 - $50.26 $232,675 - $417,057	8,298 Added 20.09%	49,610 $2.3 Million
Q3 2020 Oct 29, 2020	SELL	$27.75 - $36.3 $233,405 - $305,319	-8,411 Reduced 16.92%	41,312 $1.36 Million
Q2 2020 Jul 28, 2020	SELL	$27.21 - $41.0 $431,659 - $650,424	-15,864 Reduced 24.19%	49,723 $1.37 Million
Q1 2020 May 04, 2020	BUY	$19.54 - $38.85 $1.28 Million - $2.55 Million	65,587 New	65,587 $1.96 Million

312

237M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.01B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Stratos Wealth Partners, Ltd., based on Form 13F filings with the SEC.

Stay updated on Stratos Wealth Partners, Ltd. with notifications on news.